Social networks
1,335Activities
Technologies
Entity types
Location
13006 Marseille, France
Marseille
France
Employees
Scale: 11-50
Estimated: 17
SIREN
852807304Engaged corporates
2Added in Motherbase
1 year, 4 months agoInnovative Process Solutions
IPSOMEDIC is a pharmaceutical development company, specializing in innovation in the manufacturing of active pharmaceutical ingredients (APIs).
Our objective is to give countries the possibility to reach their pharmaceutical independance.
We design tailor-made processes for all stages of industrial production, to become cost efficient, environmental-friendly, and safe:
- Continuous chemical reaction
- Continuous purification
- Continuous crystallization
Innovation, Chemical processes, drug substance, and Continuous processes
Innovative Process Solutions
IPSOMEDIC is a pharmaceutical development company, specializing in innovation in the manufacturing of active pharmaceutical ingredients (APIs).
Our objective is to give countries the possibility to reach their pharmaceutical independance.
We design tailor-made processes for all stages of industrial production, to become cost efficient, environmental-friendly, and safe:
- Continuous chemical reaction
- Continuous purification
- Continuous crystallization
Innover pour que la fabrication en France des principes actifs pharmaceutiques, soit respectueuse de l’environnement, de nos engagements RSE et rentable pour s’assurer d’une indépendance et souveraineté médicamenteuse.
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Métropole Aix-Marseille-Provence Government Administration, French metropolis | Métropole Aix-Marseille-Provence Government Administration, French metropolis | Other | ||
Mouvement Impact France Civic and Social Organizations | Mouvement Impact France Civic and Social Organizations | Other 10 Apr 2024 | | |
Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Eurobiomed Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Other 16 Feb 2024 | |